Chimeric antigen receptor comprising BCMA nanobody linked to a chimeric intracellular signaling domain
US12263221B2 · kind B2 · utility
0Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2023 |
| Grant date | Apr 1, 2025 |
| Priority date | — |
| Expiry date | Jul 5, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application relates to functionally improved third generation BCMA-CARs comprising modified intracellular co-stimulatory domains, which can be used in adoptive cell therapy, e.g., in treatment of diseases and disorders such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.